Claims:

1. Method for the preparation of a composition containing dendritic cells and/or lymphocytes, comprising the step of culturing dendritic cells (DC) from any source in the presence of at least one IFNγ receptor agonist and of at least one toll like receptor (TLR) 2 and/or TLR 6 agonist.

2. The method of claim 1, wherein the source of DC includes progenitor derived DC, in particular monocyte derived DC and stem cell derived DC, or in vivo existent DC, in particular blood derived DC, and wherein the DC are preferably derived from autologous monocytes of a person or animal to be treated with said composition.

3. The method of claim 1 or 2, wherein the IFNγ receptor agonist is the appropriate species-specific interferon gamma or a variant thereof.

4. The method according to any one of 1 to 3, wherein the TLR 2/6 agonist is a bisacyloxypropyl-S-cystein derivative, in particular a lipopeptide derived from *Mycoplasma fermentans* or a corresponding synthetic lipopeptide capable of stimulating macrophages in vitro or in vivo, preferably Macrophage Activating Lipopeptide 2kDa (MALP-2) or biologically active derivatives thereof, in particular S-[2,3-bis(palmitoyloxy)-(2S)-propyl]-L-cysteinyl-carboxy-polyethylenglykol oder S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinyl-carboxy-polyethylenglykol.

5. The method according to any one of claims 1 to 4, wherein the treated DC are finally washed and preferably resuspended in water, saline or physiological medium.

6. The method according to any one of claims 1 to 5, wherein the DC are loaded with antigens.

7. The method according to any one of claims 1 to 6, wherein autologous or allogeneic lymphocytes acquired from the peripheal blood of donors are added, whereafter the DC and the lymphocytes and optionally further ingredients are cocultivated for a time period of up to several days, preferably at least 24 hours, more preferred at least 3 days.

8. The method according to claim 7, wherein the lymphocytes are separated from the culture and optionally washed.

9. The method according to any one of claims 1 to 8, further comprising the step of processing the composition obtained into a therapeutical composition.

10. A therapeutical composition containing DC and/or lymphocytes cocultivated with said DC, said DC have acquired the property to drive a T helper cell type I response, optainable by a method according to any one of claims 1 to 9.

11. A use of the therapeutical composition according to claim 10 as a vaccine for the treatment of malignancies, allergic disorders, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation.

12. The use of DC treated in vitro with at least one IFNγ receptor agonist in combination with at least one TLR 2 and/or TLR 6 agonist for the manufacture of a therapeutical composition for medical use, especially for the treatment of malignancies, allergic disorders, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune

disorders and host-versus-graft or graft-versus-host reactions in transplantation.

13. The use of lymphocytes cocultivated with DC treated with at least one IFNγ receptor agonist in combination with at least one TLR 2 and/or TLR 6 agonist for the manufacture of a therapeutical composition for medical use, especially for the treatment of malignancies, allergic disorders, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation.

14. The use according to claim 12 or 13, where the DC have been treated with a method according to any one of claims 1 to 8.

15. A diagnostic method to monitor the immune status of persons or animals characterized in that DC which have been prestimulated with at least one IFNγ receptor agonist and at least one TLR 2 and/or TLR 6 agonist are cocultivated with autologous or allogenic lymphocytes, whereafter proliferation, release of molecules, cytotoxic activity and/or antibody formation are measured, and the data is evaluated.

16. Pharmaceutical composition comprising effective amounts of at least one IFNγ receptor agonist and at least one TLR 2 and/or TLR 6 agonist and a pharmaceutically acceptable carrier and/or diluent.

17. A Pharmaceutical composition according to claim 16 wherein the IFNγ receptor agonist agonist is the appropriate species-specific interferon gamma or a variant thereof.

18. A pharmaceutical composition according to claim 16 or 17 wherein the TLR 2/6 agonist is a bisacyloxypropyl-S-cystein derivative, in particular a

lipopeptide derived from *Mycoplasma fermentans* or a corresponding synthetic lipopeptide capable of stimulating macrophages in vitro or in vivo, preferably Macrophage Activating Lipopeptide 2kDa (MALP-2) or biologically active derivatives thereof, in particular S-[2,3-bis(palmitoyloxy)-(2S)-propyl]-L-cysteinyl-carboxy-polyethylenglykol oder S-[2,3-bis(palmitoyloxy)-(2R)-propyl]-L-cysteinyl-carboxy-polyethylenglykol.

19. A method for treating a subject by immuntherapy comprising the step of administering an effective amount of a therapeutical composition according to claim 10 or 16 to 18 to the subject in need thereof.

20. A method according to claim 19 for the treatment of malignancies, allergic disorders, infectious disorders including viral, bacterial, fungal and parasite infections, autoimmune disorders and host-versus-graft or graft-versus-host reactions in transplantation.

21. A method according to any one of claims 19 or 20, wherein the dendritic cells and the lymphocytes are administered simultaneously, separatly or sequentially.

22. A method according to any one of claims 19 or 20, wherein the at least one IFNγ receptor agonist and the at least one TLR 2 and/or TLR 6 agonist are administered simultaneously, separatly or sequentially.

23. A method according to any one of claims 16 to 18, wherein the way of administering the composition is selected from the group consisting of oral, intradermal, subcutaneous, intravenously, inhalatively, intranasal, intranodal or by injection into or near the tumor in the case of cancer.